MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 65.86 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-13
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 57.56K shares, a 57.58% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 8.30K shares, a 95.86% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 7.08K shares.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 343.54K shares, a 489.57% increase from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 58.27K shares, a 75.10% increase from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 33.28K shares, a 97.90% decline from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 1.58M shares, a 9.85% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 57.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 65.86K shares 10-Q · filed 2026-08-13 | 65.86K shares derived: sum of 3 quarters · filed 2026-08-13 | 72.94K shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 8.30K shares 10-Q · filed 2026-05-08 | 8.30K shares derived: sum of 2 quarters · filed 2026-05-08 | 15.38K shares derived: sum of 3 quarters · filed 2026-05-08 | 151.07K shares derived: sum of 4 quarters · filed 2026-05-08 | |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 7.08K shares derived: sum of 2 quarters · filed 2026-03-31 | 142.77K shares derived: sum of 3 quarters · filed 2026-03-31 | 343.54K shares 10-K · filed 2026-03-31 | |
| 2025-09-30 | 7.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 142.77K shares derived: sum of 2 quarters · filed 2025-11-10 | 343.54K shares 10-Q · filed 2025-11-10 | 358.27K shares derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-06-30 | 135.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 336.46K shares 10-Q · filed 2025-08-14 | 351.20K shares derived: sum of 3 quarters · filed 2026-03-31 | -281.65K shares derived: sum of 4 quarters · filed 2026-03-31 | |
| 2025-03-31 | 200.77K shares 10-Q · filed 2025-05-15 | 215.50K shares derived: sum of 2 quarters · filed 2026-03-31 | -417.34K shares derived: sum of 3 quarters · filed 2026-03-31 | -417.34K shares derived: sum of 4 quarters · filed 2026-03-31 | |
| 2024-12-31 | 14.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -618.11K shares derived: sum of 2 quarters · filed 2026-03-31 | -618.11K shares derived: sum of 3 quarters · filed 2026-03-31 | 58.27K shares 10-K · filed 2026-03-31 | |
| 2024-09-30 | -632.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -632.84K shares derived: sum of 2 quarters · filed 2024-11-13 | 43.53K shares 10-Q · filed 2024-11-13 | -1.24M shares derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 676.37K shares 10-Q · filed 2024-08-14 | -604.35K shares derived: sum of 3 quarters · filed 2025-04-15 | 670.65K shares derived: sum of 4 quarters · filed 2025-04-15 | |
| 2024-03-31 | 676.37K shares 10-Q · filed 2024-05-09 | -604.35K shares derived: sum of 2 quarters · filed 2025-04-15 | 670.65K shares derived: sum of 3 quarters · filed 2025-04-15 | ||
| 2023-12-31 | -1.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -5.72K shares derived: sum of 2 quarters · filed 2025-04-15 | 33.28K shares 10-K · filed 2025-04-15 | 1.66M shares 10-K · filed 2024-03-27 | |
| 2023-09-30 | 1.27M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 1.31M shares 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | 39.00K shares 10-Q · filed 2023-08-09 | ||||
| 2022-12-31 | 447.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 1.22M shares derived: sum of 2 quarters · filed 2024-03-27 | 1.22M shares derived: sum of 3 quarters · filed 2024-03-27 | 1.58M shares 10-K · filed 2024-03-27 | |
| 2022-09-30 | 771.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | 771.00K shares derived: sum of 2 quarters · filed 2022-11-02 | 1.14M shares 10-Q · filed 2022-11-02 | ||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 366.00K shares 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 366.00K shares 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | 1.44M shares 10-K · filed 2023-03-15 | 1.44M shares 10-K · filed 2022-03-08 | |||
| 2020-12-31 | 22.00K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11 | 291.00K shares derived: sum of 2 quarters · filed 2022-03-11 | 291.00K shares derived: sum of 3 quarters · filed 2022-03-11 | 581.00K shares 10-K/A · filed 2022-03-11 | |
| 2020-09-30 | 269.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | 269.00K shares derived: sum of 2 quarters · filed 2020-11-06 | 559.00K shares 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 290.00K shares 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 290.00K shares 10-Q · filed 2020-05-11 | ||||
| 2015-09-30 | 38.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | 153.75K shares derived: sum of 2 quarters · filed 2015-11-10 | 153.75K shares 10-Q · filed 2015-11-10 | 153.67K shares derived: sum of 4 quarters · filed 2015-11-10 | |
| 2015-06-30 | 114.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | 114.86K shares 10-Q · filed 2015-08-13 | 114.78K shares derived: sum of 3 quarters · filed 2015-08-13 | ||
| 2015-03-31 | 0.00 shares 10-Q · filed 2015-05-15 | -82.00 shares derived: sum of 2 quarters · filed 2015-05-15 | |||
| 2014-12-31 | -82.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | 24.00K shares 10-K · filed 2015-03-31 | |||
| 2014-09-30 | 24.08K shares 10-Q · filed 2014-11-14 | ||||
| 2013-12-31 | 0.00 shares 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |